#USA #Orlando #Cushing's Syndrome #ISTURISA #Recordati

Recordati Highlights ISTURISA® at AACE Annual Meeting

Recordati Rare Diseases Inc. is set to unveil further details on its medication, ISTURISA® (osilodrostat), at the American Association of Clinical Endocrinology (AACE) Annual Meeting scheduled from May 15 to May 17, 2025, in Orlando, Florida. This year’s conference will showcase new indications for ISTURISA®, particularly its use in treating endogenous hypercortisolemia in adults with Cushing's syndrome when surgery is not feasible or has failed to provide a cure.

Expanded Indications for ISTURISA®

ISTURISA® is a cortisol synthesis inhibitor that functions by blocking the enzyme 11beta-hydroxylase, crucial in the biosynthesis of cortisol. As Cushing's syndrome leads to excess cortisol production, ISTURISA® is vital in normalizing these levels. Recently, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for ISTURISA®, extending its use to patients who cannot undergo surgery. This approval emphasizes the importance of continuous access to treatment for those struggling with this debilitating condition.

Dr. Mario Maldonado, Head of Development and Global Endocrinology at Recordati, expressed his enthusiasm about discussing the expanded labeling for ISTURISA® at AACE 2025. He mentioned, "This label expansion enables us to offer hope to adult patients with Cushing's syndrome who have exhausted surgical options. Additionally, I look forward to presenting data from the LINC 6 trial, which explores the long-term efficacy and safety of ISTURISA® for managing endogenous hypercortisolism." This study indicates the ongoing commitment of Recordati to improve treatment outcomes in challenging health scenarios.

Presentations and Discussions

At the AACE 2025 meeting, attendees are encouraged to visit Booth #109 for further updates regarding the new indication for ISTURISA®. Significant presentations include:

• - LINC 6 Poster Session: Focused on assessing the long-term safety and efficacy of osilodrostat in patients with endogenous Cushing's syndrome. This presentation will be delivered on May 15 from 1:30 PM to 1:45 PM EDT by Dr. Maldonado.
• - Product Theater 1 – Is Cortisol the Culprit?: An interactive panel discussion on recognizing signs and symptoms related to hypercortisolemia, taking place on May 16 from 12:15 PM to 1:00 PM EDT.
• - Product Theater 2 – Breaking Barriers in Acromegaly: A session dedicated to personalized approaches for diagnosing and treating acromegaly also scheduled for May 16.

The Importance of Awareness

The impact of hypercortisolemia on patients can be profound, leading to a myriad of health complications such as diabetes, hypertension, and increased infection risks. Raising awareness of symptoms and treatment options at such events is crucial in helping individuals receive the appropriate care and support.

About Recordati Rare Diseases Inc.

Established as a prominent player in rare disease treatments, Recordati operates on a global scale, with a steady commitment to advancing patient care across various conditions. The company, founded in Northern Italy, has expanded its reach, providing reliable treatments and conducting thorough clinical development to support its initiatives. Recordati believes health is a fundamental right, and the mission is to empower individuals to lead fuller lives, irrespective of the challenges posed by rare diseases.

Conclusion

Attendance at the AACE Annual Meeting 2025 presents a valuable opportunity for healthcare professionals and stakeholders interested in the latest advancements in endocrinology and the management of Cushing's syndrome. The insights presented by Recordati on ISTURISA® will surely influence treatment protocols and enhance patient care strategies across the board. Make sure to mark the dates and prepare your questions to gain deeper knowledge about this significant area in endocrine health.